September 20-22, 2010Hyatt Regency Boston • Boston, MA
The biopharmaceutical market is at a crossroads. Some of the biggest-selling biologics are losing their patent protection, opening up a global market estimated at over $19 billion for biosimilars, otherwise known as “follow-on biologics” or “biogenerics”. Already we are seeing changing business models as a whole new set of global competitors emerges. As the industry moves forward, it asks itself:
*What will the new biosimilars market look like?
*How do you navigate regulatory challenges?
*Who can you partner with to leverage your company?
*What product launch and marketing strategies should you use?
*How do you ensure your economic success?
IIR’s 2nd Annual Business of Biosimilars conference delivers the tools you need to succeed in the biosimilar arena. Exchange ideas and best practices surrounding innovation, regulatory change, IP protection and patent litigation strategies, and commercial management.
Join leaders and industry experts to develop effective strategies to navigate scientific, regulatory, economic, and legal challenges to remain competitive in commercializing your biosimilar portfolio in the United States and abroad.
Do You Want Your Message To Reach Top Level Decision Makers?
To learn about how you can position your company as a leader and innovator through a custom sponsorship package, please contact Andrew Sinetar at 646.895.7472 or email asinetar@iirusa.com.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment